Proteomic profiling of a biomimetic drug delivery platform

Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other hand, in the last decade, the development of bioinspired technologies was proposed as a new approach with which to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently, we developed a new drug delivery system inspired by the biology of immune cells called leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from the leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV. Here we report the proteomic profiling of the LLV and demonstrate that our approach can be used to modify the surface of synthetic particles with more than 150 leukocyte membraneassociated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium.

Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other side in the last decade, the development of bioinspired technologies was proposed as a new approach to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently we developed a new drug delivery system inspired by the biology of immune cells called Leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV, thus here we show the proteomic profiling of LLV demonstrating that our approach can be used to modify the surface of synthetic particle with more than 150 leukocyte membrane associated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium.